Back to results
US 8,771,641 B2Granted
Aryloxyanilide imaging agents
AssigneeGe Healthcare Limited
InventorsHarry John Wadsworth, Dennis O'Shea
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.
Claims9
An in vivo imaging agent of Formula I:
- wherein:
- A1 is —CR1R2—(CH2)n— wherein R1 and R2 are independently selected from hydrogen, fluoro, or C1-3 alkyl, and n is 0, 1 or 2;
- A2 is —CH2—, —O— or —O—CH2—;
- or,
- -A1-A2- is —CH═CH—.
2 more elements
Dependencies are inferred from the claim text.